News | January 04, 2007

Docs, Investors Await News on Plaque Drug

Jan. 5, 2007 — An announcement from AstraZeneca is expected soon about the company’s experimental heart drug AGI-1067, the company’s partner AtheroGenics Inc. hopes to present results from a pivotal Phase III clinical trial to the American College of Cardiology (ACC) meeting in New Orleans. Deadline for research submissions was yesterday, and therefore, analysts surmise, AtheroGenics may be negotiating with ACC what news it and AstraZeneca can release to investors prior to the meeting.

An AstraZeneca spokesman said the news was still expected early in 2007. Meanwhile Atherogenics CEO Russell Medford is slated to address J.P. Morgan's annual healthcare conference Jan. 10.

In December of 2005 AstraZeneca agreed to pay AtheroGenics up to $1 billion for exclusive rights to AGI-1067, an anti-inflammatory product designed to reduce the build-up of plaque inside arteries that can lead to heart attack and stroke.

AGI-1067 belongs to a small group of experimental medicines aimed at treating atherosclerosis. If successful, it and rival products from GlaxoSmithKline and Iceland's Decode Genetics Inc. could be the next major advance in treating heart disease — current treatments for atherosclerosis are anti-inflammatory drugs, which reduce the risk of disease progressing by only 30 to 35 percent.

In December, Pfizer Inc.’s key new medicine torcetrapib, did not prove to be successful in raising levels of "good" HDL cholesterol.

Related Content

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Overlay Init